Back to search results
NCT07029542

Home Reported Outcomes in C3G Study

Recruiting
Not specifiedAges 18+Observational
Novartis Pharmaceuticals
~100 participants
Updated 2025-06-19 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants reporting the top 10 symptoms most frequently self-reported
Measured over 6 months
+2 more outcomes measured

Conditions

C3 Glomerulopathy

Explore related trials

C3 glomerulopathy

Where it's being run

1 sites across 1 states
New Jersey1

Study leadership

  • Novartis Pharmaceuticals · STUDY_DIRECTOR · Novartis Pharmaceuticals

Who to contact

Novartis Pharmaceuticals
[email protected]
1-888-669-6682
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of C3G, regardless of symptom, treatment, or transplant history
Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
Able to provide informed consent
Has access to technology (i.e. mobile phone, tablet) that facilitates their participation in the app-based study
US-based with a proficient understanding of and ability to read the English language

What this trial measures

  • Number of participants reporting the top 10 symptoms most frequently self-reported6 months

    Identification of the top 10 symptoms most frequently self-reported by participants, as well as the total number of participants reporting each of those symptoms

  • Participant average of self-reported severity of each of the top 10 symptoms6 months

    Across-participant average (and standard deviation) of self-reported severity of each of the top 10 symptoms over the course of the 6-month study

  • Within-participant variability in self-reported severity of each of the top 10 symptoms6 months

    Within-participant variability in self-reported severity of each of the top 10 symptoms over the course of the 6-month study